Ting-Yi Liang1, Xiu-Yu Zhu1, Xu-Ming Hua2, Xun-Da Ji1, Pei-Quan Zhao1. 1. Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China. 2. Department of Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
Abstract
AIM: To evaluate the efficacy and safety of combined intra-arterial chemotherapy (IAC) and intravitreal melphalan (IVM) for the treatment of advanced unilateral retinoblastoma. METHODS: This retrospective study involved 30 consecutive eyes from 30 Chinese patients with advanced unilateral retinoblastoma. All patients were initially treated with IAC combined with IVM. The clinical status and complications were recorded at each visit. RESULTS: The International Intraocular Retinoblastoma Classification groups were D in 23 eyes and E in 7 eyes. All eyes showed severe cloud vitreous seeds at the first visit. The mean number of IAC cycles and intravitreal injections was 3.2 (range, 3-4) and 6 (range, 1-14), respectively. The median follow-up time was 29mo (range, 7-36mo). Treatment success with regression of the retinal tumor and vitreous seeds was achieved in 29 of 30 eyes (96.7%). Globe salvage was attained in 93.3% (28/30) eyes, and enucleation (n=2) was performed due to neovascular glaucoma and persistent vitreous hemorrhage. Complications included retinal pigment epithelium (RPE) atrophy (n=13; 43%), mild lens opacity (n=7; 23%), vitreous hemorrhage (n=5; 17%) and rhegmatogenous retinal detachment (n=1; 3%). No extraocular tumor extension or metastasis occurred. CONCLUSION: Combined IAC and IVM is effective and safe for the treatment of advanced unilateral retinoblastoma. International Journal of Ophthalmology Press.
AIM: To evaluate the efficacy and safety of combined intra-arterial chemotherapy (IAC) and intravitreal melphalan (IVM) for the treatment of advanced unilateral retinoblastoma. METHODS: This retrospective study involved 30 consecutive eyes from 30 Chinese patients with advanced unilateral retinoblastoma. All patients were initially treated with IAC combined with IVM. The clinical status and complications were recorded at each visit. RESULTS: The International Intraocular Retinoblastoma Classification groups were D in 23 eyes and E in 7 eyes. All eyes showed severe cloud vitreous seeds at the first visit. The mean number of IAC cycles and intravitreal injections was 3.2 (range, 3-4) and 6 (range, 1-14), respectively. The median follow-up time was 29mo (range, 7-36mo). Treatment success with regression of the retinal tumor and vitreous seeds was achieved in 29 of 30 eyes (96.7%). Globe salvage was attained in 93.3% (28/30) eyes, and enucleation (n=2) was performed due to neovascular glaucoma and persistent vitreous hemorrhage. Complications included retinal pigment epithelium (RPE) atrophy (n=13; 43%), mild lens opacity (n=7; 23%), vitreous hemorrhage (n=5; 17%) and rhegmatogenous retinal detachment (n=1; 3%). No extraocular tumor extension or metastasis occurred. CONCLUSION: Combined IAC and IVM is effective and safe for the treatment of advanced unilateral retinoblastoma. International Journal of Ophthalmology Press.
Authors: Carol L Shields; Fairooz P Manjandavida; Sruthi Arepalli; Swathi Kaliki; Sara E Lally; Jerry A Shields Journal: JAMA Ophthalmol Date: 2014-03 Impact factor: 7.389
Authors: Carol L Shields; Carlos G Bianciotto; Pascal Jabbour; Aparna Ramasubramanian; Sara E Lally; Gregory C Griffin; Robert Rosenwasser; Jerry A Shields Journal: Arch Ophthalmol Date: 2011-06-13
Authors: Paula Schaiquevich; Emiliano Buitrago; Paula Taich; Ana Torbidoni; Alejandro Ceciliano; Adriana Fandino; Marcelo Asprea; Flavio Requejo; David H Abramson; Guillermo F Bramuglia; Guillermo L Chantada Journal: Invest Ophthalmol Vis Sci Date: 2012-06-28 Impact factor: 4.799
Authors: Christina Stathopoulos; Marie-Claire Gaillard; Alexandre Moulin; Francesco Puccinelli; Maja Beck-Popovic; Francis L Munier Journal: Retina Date: 2019-12 Impact factor: 4.256
Authors: Jasmine H Francis; David H Abramson; Marie-Claire Gaillard; Brian P Marr; Maja Beck-Popovic; Francis L Munier Journal: Ophthalmology Date: 2015-03-18 Impact factor: 12.079
Authors: Peter E Zage; Aaron J Reitman; Roopa Seshadri; Joanna L Weinstein; Marilyn B Mets; Janice Lasky Zeid; Mark J Greenwald; Lewis C Strauss; Stewart Goldman Journal: Pediatr Blood Cancer Date: 2008-03 Impact factor: 3.167
Authors: Arthur Aubry; Joel D Pearson; Katherine Huang; Izhar Livne-Bar; Mohammad Ahmad; Madhavan Jagadeesan; Vikas Khetan; Troy Ketela; Kevin R Brown; Tao Yu; Suying Lu; Jeffrey L Wrana; Jason Moffat; Rod Bremner Journal: Oncogene Date: 2020-06-22 Impact factor: 9.867